Active components and action mechanism of Shenmai Injection in treatment of atrial fibrillation based on network pharmacology and molecular docking.
10.19540/j.cnki.cjcmm.20210609.704
- Author:
Yi-Xin WANG
1
;
Peng LIU
1
;
Tong LI
1
;
Xing-Hua QIN
2
;
Qiang-Sun ZHENG
1
Author Information
1. Department of Cardiology, the Second Affiliated Hospital of Xi'an Jiaotong University Xi'an 710004, China.
2. School of Life Sciences, Northwestern Polytechnical University Xi'an 710072, China.
- Publication Type:Journal Article
- Keywords:
Shenmai Injection;
active component;
atrial fibrillation;
mechanism;
molecular docking;
network pharmacology
- MeSH:
Atrial Fibrillation/drug therapy*;
Drug Combinations;
Drugs, Chinese Herbal;
Humans;
Medicine, Chinese Traditional;
Molecular Docking Simulation
- From:
China Journal of Chinese Materia Medica
2021;46(17):4511-4521
- CountryChina
- Language:Chinese
-
Abstract:
This study aims to explore the active components and molecular mechanism of Shenmai Injection in the treatment of atrial fibrillation(AF) based on the application of network pharmacology and molecular docking technology. The chemical components of single herbs of Shenmai Injection were collected from TCMSP and TCMID, with the standard chemical name and PubChem CID(referred to as CID) obtained from PubChem database. The active components were screened using SwissADME, and their targets were predicted using SwissTargetPrediction. Targets related to AF treatment were identified using GeneCards, OMIM, and other databases. Venn diagram was constructed using Venny 2.1 to obtain the intersection targets. The single herb-active component-potential target network was constructed using Cytoscape, and the clusterProfiler R function package was used to perform the gene ontology(GO) and Kyoto encyclopedia of genes and genomes(KEGG) pathway enrichment. The protein-protein interaction(PPI) network of intersection targets was generated based on the STRING database. The hub target protein was identified by visualization using Cytoscape, and then docked to its reverse-selected active components. The analysis showed that there were 65 active components with 681 corresponding targets in Shenmai Injection, 2 798 targets related to AF treatment, and 235 intersection targets involving 2 549 GO functions and 153 KEGG pathways. Finally, hub target proteins, including RAC-alpha serine/threonine-protein kinase(AKT1), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha(PIK3 CA), and estrogen receptor 1(ESR1), were screened out by PPI network visualization. The molecular docking was performed for 39 active components screened out in reverse, among which 30 active components de-monstrated high affinity. Among them, homoisoflavanoids CID 10871974, CID 5319742, and CID 10361149 had stronger affinity docking with AKT1. This study preliminarily indicates that Shenmai Injection treats AF through multiple components, multiple targets, and multiple pathways. Homoisoflavonoids of Ophiopogon japonicus are its important active components, which target AKT1 to regulate metabolism, inflammation, and apoptosis in AF treatment.
